# The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

> **NCT05213143** · PHASE4 · TERMINATED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 13 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone

## Key facts

- **NCT ID:** NCT05213143
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-30
- **Primary completion:** 2022-11-18
- **Final completion:** 2022-11-18
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Company's business decision
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213143, "The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05213143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*